Howard C. Dittrich, M.D.

Howard is a cardiologist with more than 20 years of experience in cardiac therapeutic research and clinical development.

He previously co-founded and served as the chief medical officer of Hawkeye Therapeutics and Sequel Pharmaceuticals. He served as chief medical officer for Laguna Pharmaceuticals and Sorbent Therapeutics. Prior to that, he served as chief medical officer at NovaCardia until its acquisition by Merck & Co., Inc. Howard is also an entrepreneur-in-residence at Frazier Healthcare Partners and serves as president and a member of the board of directors of Advanced Endovascular Therapeutics, Inc., a private biotechnology company that he co-founded.

Howard is an adjunct professor of medicine at the University of Iowa Carver College of Medicine and chair of the board of directors of the François M. Abboud Cardiovascular Research Center. He previously served as a full-time faculty member of the department of medicine, and later, as a part-time clinical professor of medicine, at the University of California, San Diego.

Howard received his M.D. from the University of Iowa Carver College of Medicine and a B.S. from the University of Iowa. He completed his residency in internal medicine and clinical fellowship in cardiology at the University of California, San Diego.